RxDoctor Payments Data

Madeline Fields, MD

Clinical Neurophysiology · New York, NYNPI 1962667360

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,127 of the $5,452 with a category attached, or 75.7%. 14 manufacturers reported payments, led by Neuropace, Inc. at 32.8% of the total. Reporting peaked in 2019 at $3,133 and has fallen 73.8% since, to $820 in 2025.

$5,452in general payments, 2019–2025

Across 145 payments — averaging $37.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • UCB, Inc.$716
  • SK Life Science, Inc.$446
  • Greenwich Biosciences, Inc.$392
  • Neurelis, Inc.$344
  • plus $608 from 8 others

What the payments were for

  • Travel & lodging$1,27523%
  • Food & beverage$4,12776%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,452 in reported general payments places this provider in the 80th percentile of 35 clinical neurophysiology providers in New York.

See all clinical neurophysiology providers in New York

Medicare billing

Part B allowed, 2024
$103,886
Medicare patients
311
Services billed
763

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)22$78,351
BriviactBrivaracetam24$28,657
Topiramate ErTopiramate12$19,456
AptiomEslicarbazepine Acetate11$17,476
Oxcarbazepine51$10,364
XcopriCenobamate11$9,541
Divalproex Sodium18$7,409
Lacosamide95$6,363
Clobazam52$5,255
Levetiracetam134$4,473
Levetiracetam ErLevetiracetam44$4,464
Lamotrigine ErLamotrigine22$4,340
DilantinPhenytoin Sodium Extended11$1,788
Valproic AcidValproic Acid (As Sodium Salt)12$1,512
Zonisamide29$1,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$716$28,65724 claims
Sunovion Pharmaceuticals Inc.Aptiom$63$17,47611 claims
SK Life Science, Inc.Xcopri$446$9,54111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 35 clinical neurophysiology providers in New York.

Other clinical neurophysiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →